1Ishak K,Baptista A,Bianchi L,et al.Histological grading and staging of chronic hepatitis.J Hepatol,1995,22:696-699.
2Takimoto M,Ohkoshi S,Ichida T,et al.Interferon inhibits progression of liver fibrosis and rreduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C:a retrospective multicenter analysis of 652 patients.Dig Dis,2002,47:170-176.
3Caballero T,Perez-Milena A,Masseroli M,et al.Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon treated patients with chronic hepatitis J Hepatol,2001,34:740-747.
4Jarmay K,Gallai M,Karacsony G,et al.Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alfa-2b treatment.J Hepatol,2000,32:933-1002.
7Hemmann S, Graf J, Roderfeld M, et al. Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies [ J ]. J Hepatol, 2007, 46 (5) : 955 - 975.
8Mitsuda A, Suou T, Ikuta Y, et al. Changes in serum tissue inhibitor of matrix metdloproteinase-1 after interferon alpha treatment in chronic hepatitis C[J]. J Hepatol, 2000, 32(4): 666-672.
